Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans

  • STATUS
    Recruiting
  • End date
    Sep 1, 2024
  • participants needed
    108
  • sponsor
    University of Minnesota
Updated on 19 January 2022
ketamine
depression
probe
antidepressants
suicidal
major depressive disorder
chronic post-traumatic stress disorder

Summary

Co-occurring post-traumatic stress disorder (PTSD) and major depressive disorder (MDD) is the most common response to trauma; it is associated with poor clinical outcomes and substantial human disability. Veterans with both PTSD and MDD (PTSD+MDD) have been shown to be at much greater suicidal risk than individuals with only one of these disorders. Ketamine given as repeated infusions has been shown to be effective in rapidly reducing PTSD and MDD symptoms in treatment resistant PTSD+MDD individuals. However, knowledge about the mechanisms underlying comorbid PTSD and MDD remain limited. The purpose of this study is to use repeated ketamine infusions as a probe to validate a model of PTSD+MDD that focuses on neuroanatomy and executive functioning.

Description

This study is designed to better characterize the neurocognitive and associated functional connectivity mechanisms underlying comorbid post-traumatic stress disorder (PTSD) and major depressive disorder (MDD) among veterans. Participants will be male/female veterans (18 to 75 years old) of any era or military background who suffer from chronic PTSD and MDD. Potential participants will be recruited from mental health clinics and screened for eligibility using a two stage process (phone/chart review, followed by interview). Participants with PTSD+MDD will undergo a series of baseline assessments including a baseline functional magnetic resonance imaging (fMRI) then be randomized to receive either 6 ketamine or 6 normal saline infusions on a Monday-Friday schedule over 3 weeks. On the day of infusion, participants will be required to stay at the clinical site for 2 hours after the infusion has been given. They will also be monitored via a phone call on the following day. After the infusion period has been completed participants will undergo a follow-up fMRI then 4 follow-up visits, up to 2 months. Additional participants will be enrolled in healthy control, depression only, and PTSD only groups and will only undergo baseline assessments, including a single fMRI.

Details
Condition Major depression, Endogenous depression, Post-Traumatic Stress Disorder, Post-Traumatic Stress Disorders, Post-Traumatic Stress Disorders, major depressive disorder, PTSD, major depressive disorders
Treatment Ketamine, Normal saline
Clinical Study IdentifierNCT04032301
SponsorUniversity of Minnesota
Last Modified on19 January 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

For the PTSD+MDD group, inclusion criteria are
Female/Male veterans
18 to 75 years old
Meets DSM-5 criteria for MDD, single or recurrent, moderate-severe without psychotic features
Meets DSM-5 criteria for chronic PTSD or subthreshold PTSD [meets criterion A (traumatic event), criterion B (intrusion symptoms), and 2 of the following 3 criteria: C (avoidance symptoms), D (negative alterations in cognitions and mood), or E (marked alterations in arousal and reactivity)]
If applicable, 6 weeks of stable antidepressants/augmenting agents
Sixth grade reading level
Ability to provide consent
For the Healthy Controls group, inclusion criteria are
Female/Male veterans
18 to 75 years old
Does not meet DSM-5 criteria for MDD, single or recurrent, moderate-severe without psychotic features
Does not meet DSM-5 criteria for chronic PTSD or subthreshold PTSD
Not on medications for managing a psychiatric indication
Sixth grade reading level
Ability to provide consent
For the Depression-only group, inclusion criteria are
Female/Male veterans
18 to 75 years old
Experienced a traumatic event that meets DSM-5 criterion A for a diagnosis of PTSD but does not meet sufficient criteria (B-E) necessary for a diagnosis of PTSD or subthreshold PTSD
Meets criteria for MDD, single or recurrent, moderate-severe
If applicable, 6 weeks of stable antidepressants/augmenting agents
Sixth grade reading level
Ability to provide consent
For the PTSD-only group, inclusion criteria are
Female/Male veterans
18 to 75 years old
Meets DSM-5 criteria for chronic PTSD or subthreshold PTSD [meets criterion A (traumatic event), criterion B (intrusion symptoms), and 2 of the following 3 criteria: C (avoidance symptoms), D (negative alterations in cognitions and mood), or E (marked alterations in arousal and reactivity)]
Does not meet DSM-5 criteria for MDD, single or recurrent, moderate-severe without psychotic features
If applicable, 6 weeks of stable antidepressants/augmenting agents
Sixth grade reading level
Ability to provide consent

Exclusion Criteria

For the PTSD+MDD group, exclusion criteria are
Inability or unwillingness to provide written informed consent
Moderate/severe cognitive impairment
Current or lifetime diagnosis of psychosis-related disorder, bipolar I or II disorder, substance-induced mood disorder, or any mood disorder due to a general medical condition
History of moderate or severe traumatic brain injury
History of comorbid substance disorder within 1 month of screening
Prior use of ketamine as an antidepressant
Clinically unstable medical illness
For women: pregnancy (confirmed by baseline lab test), the initiation of female hormonal treatments within 3 months of screening, or inability or unwillingness to use a medically accepted contraceptive method for the duration of the study
Imminent risk of suicidal/homicidal ideation and/or behavior
Inability to undergo MRI (i.e. claustrophobia, ferromagnetic implants, etc.)
For the Healthy Controls group, exclusion criteria are
Inability or unwillingness to provide written informed consent
Moderate/severe cognitive impairment
History of any major medical or psychiatric disorders
Current or lifetime diagnosis of psychosis-related disorder, bipolar I or II disorder, substance-induced mood disorder, or any mood disorder due to a general medical condition
History of moderate or severe traumatic brain injury
History of comorbid substance disorder within 1 month of screening
Prior use of ketamine as an antidepressant
Clinically unstable medical illness
For women: pregnancy (confirmed by baseline lab test), the initiation of female hormonal treatments within 3 months of screening, or inability or unwillingness to use a medically accepted contraceptive method for the duration of the study
Imminent risk of suicidal/homicidal ideation and/or behavior
Inability to undergo MRI (i.e. claustrophobia, ferromagnetic implants, etc.)
For the Depression-only group, exclusion criteria are
Inability or unwillingness to provide written informed consent
Moderate/severe cognitive impairment
Meet DSM-5 criteria for PTSD or subthreshold PTSD
Current or lifetime diagnosis of psychosis-related disorder, bipolar I or II disorder, substance-induced mood disorder, or any mood disorder due to a general medical condition
History of moderate or severe traumatic brain injury
History of comorbid substance disorder within 1 month of screening
Prior use of ketamine as an antidepressant
Clinically unstable medical illness
For women: pregnancy (confirmed by baseline lab test), the initiation of female hormonal treatments within 3 months of screening, or inability or unwillingness to use a medically accepted contraceptive method for the duration of the study
Imminent risk of suicidal/homicidal ideation and/or behavior
Inability to undergo MRI (i.e. claustrophobia, ferromagnetic implants, etc.)
For the PTSD-only group, exclusion criteria are
Inability or unwillingness to provide written informed consent
Moderate/severe cognitive impairment
Meet DSM-5 criteria for a diagnosis of MDD, single or recurrent, moderate to severe
Current or lifetime diagnosis of psychosis-related disorder, bipolar I or II disorder, substance-induced mood disorder, or any mood disorder due to a general medical condition
History of moderate or severe traumatic brain injury
History of comorbid substance disorder within 1 month of screening
Prior use of ketamine as an antidepressant
Clinically unstable medical illness
For women: pregnancy (confirmed by baseline lab test), the initiation of female hormonal treatments within 3 months of screening, or inability or unwillingness to use a medically accepted contraceptive method for the duration of the study
Imminent risk of suicidal/homicidal ideation and/or behavior
Inability to undergo MRI (i.e. claustrophobia, ferromagnetic implants, etc.)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note